Medication Study for those with Remitting Relapsing Multiple Sclerosis who have not responded to other Treatments (Ages 18-55)
Official Title
AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT
Purpose
The purpose of this study is to determine the effectiveness of the drug ocrelizumab in those with Remitting Relapsing Multiple Sclerosis who have not had good outcomes with other Disease-Modifying Treatment.
Could this study be right for you?
You may be eligible for this study if you:
- are between the ages of 18 and 55 years
- have a definite diagnosis of Relapsing Remitting MS
- have a length of disease duration (from first symptom) of less than or equal to 8 years
- have been treated with no more than 2 prior disease-modifying treatments (discontinued due to lack of efficiency)